Extended Data Fig. 5: Emergence of in vitro resistance in PTV dose-escalation studies.
From: Structural and mechanistic insights into herpesvirus helicase–primase and its therapeutic inhibitors
a, Cells infected with HSV-1 (blue) or HSV-2 (purple) were grown in the presence of PTV. When cytopathic effect was observed, virus from the culture supernatants was used to infect a fresh monolayer of cells in the presence of an increased concentration of PTV. Changes in HSV-1 and HSV-2 UL5/UL52 sequences compared to baseline (prior to PTV exposure) are indicated. DMSO-only passaged virus was used as a negative control for variant calling. b, Phenotyping of indicated HSV-2 variants was performed in ARPE-19 cells by measuring mCherry expression. Representative dose-response curves with a mean EC50 ± SD value from n = 3 independent experiments are shown. Data on graph are mean ± SD from 3-6 replicates per condition.
